Cagrilintide [obesity and type 2 diabetes]

Cagrilintide Vials 5mg, 10mg, 15mg ,99% Purity Peptides
Cagrilintide is an investigational long-acting amylin analogue developed for the treatment of obesity and overweight in individuals with or without type 2 diabetes. It mimics the physiological effects of endogenous amylin, a hormone co-secreted with insulin, to regulate appetite and food intake. Cagrilintide works by delaying gastric emptying and increasing satiety signals in the brain, leading to reduced caloric intake and body weight. It is being evaluated as a once-weekly subcutaneous injection, often in combination with GLP-1 receptor agonists such as semaglutide, to enhance weight loss outcomes.

Gizem Peptides – Premium Research Peptides for Global Distribution

Cagrilintide Vials (5mg, 10mg, 15mg) – ≥99% Purity

Gizem Peptides proudly offers high-purity Cagrilintide in multiple vial concentrations (5mg, 10mg, and 15mg), designed to meet the rigorous standards of international research and wholesale markets. Manufactured under strict quality control protocols, our Cagrilintide peptides deliver ≥99% purity, ensuring consistency, reliability, and performance for professional applications.

Cagrilintide is an advanced, long-acting amylin analogue currently under investigation for its role in weight management and metabolic research. It is structurally designed to replicate the physiological activity of endogenous amylin, a naturally occurring hormone co-secreted with insulin that plays a key role in regulating appetite, gastric motility, and energy intake.

Mechanistically, Cagrilintide functions by slowing gastric emptying, prolonging satiety, and modulating appetite signals within the central nervous system. These combined effects contribute to reduced caloric consumption and potential body weight reduction. Due to its extended duration of action, it is being studied as a once-weekly subcutaneous formulation, offering convenience and improved compliance in research settings.

Cagrilintide is also gaining significant attention in combination protocols, particularly alongside GLP-1 receptor agonists such as semaglutide, where synergistic effects may further enhance weight management outcomes and metabolic regulation.

Key Features:

  • Available in 5mg, 10mg, and 15mg vial formats
  • ≥99% purity for high-quality research applications
  • Long-acting amylin analogue with extended activity profile
  • Stable formulation suitable for global shipping and storage
  • Increasing demand in metabolic and obesity-related research markets

Wholesale & Distribution:
Gizem Peptides supports bulk purchasing, private labeling, and international logistics, making us a reliable partner for distributors, laboratories, and research institutions worldwide. Our supply chain is optimized for timely delivery, competitive pricing, and scalable volume orders to meet growing global demand.

Reviews

There are no reviews yet.

Be the first to review “Cagrilintide [obesity and type 2 diabetes]”

Your email address will not be published. Required fields are marked *

Scroll to Top